Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Celltrion Pharmaceutical company has finally completed merging with its Celltrion Healthcare affiliate. This comes after the board of directors has given the “go-ahead” signal for the merger on Thursday, Dec. 28.
The unification of Celltrion and Celltrion Healthcare happened three years after the plan was first announced by the former. According to Korea Joongang Daily, the newly formed entity, following the completion of the affiliation, will then proceed to go into another merger process, this time with Celltrion Pharm. This second deal is expected to be completed sometime next year.
New Unified Entity to Enter Another Merger Deal
The new company was formed after Celltrion and Celltrion Healthcare were successfully consolidated into one entity. This will be merged with Celltrion Pharma, and the resulting new organization will have Celltrion Holdings as its largest shareholder with a 21.5% share.
In any case, it was mentioned that Celltrion’s founder and chairman, Seo Jung Jin, still has a 98.1% stake in the group’s holdings firm. As three firms are being consolidated with this succession of mergers, the company is aiming to reach KRW2 trillion won or about $9 billion in annual revenue by the year 2030.
“Celltrion was able to secure massive funds through the merger and will invest them in our new future growth engines like biosimilars, new drug development and mergers and acquisitions,” Celltrion commented.
Appointment of Three CEOs for the Merged Company
The integrated Celltrion company is set to be managed by three chief executive officers. Korea’s Alphabiz reported that the appointed executives include Ki Woo Sung, who will supervise the manufacturing and development division; Kim Hyung Ki, who will be assigned to manage the global sales unit; and Seo Jin Seok, who will become head of the business management unit.
Celltrion will start operating as a representative system for the three chiefs soon.
Photo by: Celltrion Media Center
